Loss of endogenous thymosin β<sub>4</sub> accelerates glomerular disease.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 27575556.
- Also identified by DOI 10.1016/j.kint.2016.06.032 and PMC identifier 5073078.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Glomerular disease is characterized by morphologic changes in podocyte cells accompanied by inflammation and fibrosis. Thymosin β<sub>4</sub> regulates cell morphology, inflammation, and fibrosis in several organs and administration of exogenous thymosin β<sub>4</sub> improves animal models of unilateral ureteral obstruction and diabetic nephropathy. However, the role of endogenous thymosin β<sub>4</sub> in the kidney is unknown. We demonstrate that thymosin β<sub>4</sub> is expressed prominently in podocytes of developing and adult mouse glomeruli. Global loss of thymosin β<sub>4</sub> did not affect healthy glomeruli, but accelerated the severity of immune-mediated nephrotoxic nephritis with worse renal function, periglomerular inflammation, and fibrosis. Lack of thymosin β<sub>4</sub> in nephrotoxic nephritis led to the redistribution of podocytes from the glomerular tuft toward the Bowman capsule suggesting a role for thymosin β<sub>4</sub> in the migration of these cells. Thymosin β<sub>4</sub> knockdown in cultured podocytes also increased migration in a wound-healing assay, accompanied by F-actin rearrangement and increased RhoA activity. We propose that endogenous thymosin β<sub>4</sub> is a modifier of glomerular injury, likely having a protective role acting as a brake to slow disease progression.
Medical subject headings
- Glomerulonephritis
- Podocytes
- Thymosin